黑料吃瓜群网

Cirrhosis (scarring of the liver) is responsible for approximately 300,000 deaths each year worldwide. Now, researchers have developed a genetic risk score (GRS) test to help identify patients at high risk of developing alcohol-related cirrhosis.

In their study an international research group, led by the , found that a high GRS from the test of excessive alcohol consumers meant a threefold increase in cirrhosis risk. The presence of diabetes together with a high GRS increased the cirrhosis risk among drinkers more than tenfold.

Dr John Whitfield from and lead author of the study said the test had been developed by examining samples from patients with and without alcohol-related cirrhosis, but all with a history of heavy alcohol consumption.

鈥淭his was classified as men consuming more than 80 grams (8 standard drinks) of alcohol daily and women more than 50 grams daily, both for a time period of 10 or more years.鈥�

鈥淩isk scores were computed by the analysis of up to eight gene variations and three clinical risk factors (including type 2 diabetes) associated with alcohol-related cirrhosis,鈥� Dr Whitfield said.

鈥淲e鈥檝e shown that a GRS based on only three genetic risk variants plus diabetes status can be extremely meaningful in determining overall cirrhosis risk. Our test will allow for early and personalised management of high-risk patients,鈥� said Clinical Associate Professor Seth, also a Principal Scientist at the Edith Collins Centre, Royal Prince Alfred 黑料吃瓜群网, Sydney Local Health District.

Clinical Associate Professor Devanshi Seth, Head of the Centenary Institute鈥檚 Alcoholic Liver Disease Research Program and joint senior author of the study, said the test helps identify at-risk individuals at an early stage enabling the application of focused interventions. 鈥淓vidence suggests that even just informing excessive drinkers that they have an increased cirrhosis risk may motivate them to reduce their alcohol intake, helping prevent serious disease,鈥� Seth said.

The study, published in the Journal of Hepatology, was undertaken by the multinational GenomALC Consortium with USA co-lead Dr Timothy R Morgan from the Southern California Institute of Research and Education; and funded by the a part of the , USA.

Image credit:聽漏stock.adobe.com/au/Rasi